-
Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 3 February 2012
BAGSVAERD, DENMARK--(Marketwire - Feb 6, 2012) -
-
Market Research Estimates Biomarker Market at $13 Billion
-
Yubico and SSO Easy Make Single Sign-On With Two-Factor Authentication Easier
PALO ALTO, CA and STOCKHOLM, SWEDEN--(Marketwire - Feb 6, 2012) - Easy and cost-efficient two-factor authentication for single sign-on is now made available by a partnership between Yubico, the leading provider of simple, open online identity protection, and SSO Easy, provider of SAML server solutions.
-
Cegedim Strategic Data (CSD) Tracks Pharmaceutical Companies' Print Advertising Investments
Rate of Decline in Print Advertising Investments Slows to 4% for 12 Months Ending September 2011 Across Ten Key Markets
-
Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs
STOCKHOLM, SWEDEN--(Marketwire - Feb 6, 2012) - Sobi and Biogen Idec have agreed to
disclose further details on their agreement
regarding development and commercialization of long-lasting recombinant
factor
VIII and factor IX hemophilia programs, which was restructured in February
2010. Under the new agreement, Biogen Idec assumed full development
responsibilities and costs, as well as manufacturing rights. In addition,
the
cross-royalty rates were reduced and commercial rights for certain
territories
were changed.
-
Pyng Medical Corp. Announces Bridge Loan
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2012) - Pyng Medical Corp. (TSX VENTURE:PYT) ("Pyng" or the "Company") today announced a loan (the "Loan") in the amount of US$220,000 from its largest shareholder Excelera Corporation ("Excelera"). The Loan carries interest at 11% per annum, is unsecured, and does not include an equity component. The total principal and interest is due on April 12, 2012.
-
The Medicines Company to Announce Fourth Quarter and Full Year 2011 Financial Results on Wednesday, February 22, 2012
Conference Call to Be Held at 8:30 a.m. Eastern Time
-
Elderly Alerts, Leader in Medical Alert Systems, Educates the Elderly Community via Twitter
Through Social Media, Elderly Alerts Educates on the Importance of Having Medical Alert Alarms at Home
-
Intergraph(R) Webinars on February 15 and 16 to Demonstrate How to Modify Pipe Specifications Using New CADWorx(R) DraftPro(TM) for Intelligent 2D Plant Design
HOUSTON, TX--(Marketwire - Feb 3, 2012) - Intergraph has scheduled CADWorx DraftPro webinars on February 15 at 10:00 a.m. and February 16, 2012 at 7:00 p.m. CT that will cover how to get started with pipe specifications, line numbers, and layouts using this new AutoCAD®-based intelligent 2D plant design and layout solution. The webinar will show how the built-in editor allows you to easily modify the supplied piping specifications to match your exact needs, saving time and providing accurate bills of material that require no manual modification. The webinar leader will be Sonia Delgadillo, senior CADWorx applications specialist at Intergraph CADWorx & Analysis Solutions group.
-
CardioComm Solutions, Inc. Issues Stock Options
TORONTO, ONTARIO--(Marketwire - Feb. 3, 2012) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today announced that it has granted 100,000 incentive stock options to Mr. Simi Grossman, an independent member of the board of directors. The options are exercisable at $0.355 per share, based on markets prior day's close, for five years from the date of grant, are vested equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.
-
Insulet Corporation to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012
BEDFORD, MA--(Marketwire - Feb 3, 2012) - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2011 on February 9, 2012 after the close of the financial markets.
-
Corporate Profile's CPreports.com Publishes Article by Ray Dirks of Ray Dirks Research on Medgenics
NEW YORK, NY--(Marketwire - Feb 3, 2012) - Corporate Profile's financial website www.CPreports.com announces Ray Dirks article on Medgenics, Inc. (NYSE Amex: MDGN).
-
CardioComm Solutions, Inc. Announces Equity Financing
TORONTO, ONTARIO--(Marketwire - Feb. 3, 2012) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") today announced that it will be conducting a non-brokered private placement equity financing under which it intends to issue up to 4,000,000 units at a price of $0.50 per unit for gross proceeds of $2,000,000. Each unit will be comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.75. The securities to be issued under the financing will be subject to a four month hold period.
-
Novo Nordisk A/S : Trading in Novo Nordisk shares by board members, executives and associated persons on 2 February 2012
BAGSVAERD, DENMARK--(Marketwire - Feb 3, 2012) -
-
Cerecor Announces Scientific Advisory Board
BALTIMORE, MD--(Marketwire - Feb 3, 2012) - Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced the members of its Scientific Advisory Board, established to supplement its management team.
-
BC Bioenergy Network Invests $1.5 M in Fraser Richmond Soil and Fibre "Energy Garden"-an Innovative Organic Waste to Energy Demonstration
RICHMOND, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2012) - The BC Bioenergy Network ("BCBN"), a provincially-funded not for profit organization supporting the acceleration of bioenergy development in British Columbia, announced funding of $1.5 M to Fraser Richmond Soil and Fibre, a Harvest Power company. The project will establish an "EnergyGarden", an innovative municipal green (food and yard) waste to renewable energy demonstration in the Lower Mainland that will divert 27,000 tonnes of organic materials away from British Columbia landfills.
-
Methodist Orthopedics and Sports Medicine Specialists Named Among 2011-2012 Texas Super Doctors -- Featured in Texas Monthly as Best in Texas Healthcare
Travis Hanson M.D., Korsh Jafarnia M.D., Bruce Moseley M.D., Scott Rand M.D., Plinio Caldera M.D., Greg Seelhoefer M.D. and HoSun Hwang M.D. Among the Elite Orthopedic and Sports Medicine Specialists Featured in the Recently Released Super Doctors Issue
-
McKesson Corporation Acquires Proventys' Advanced Decision Support Assets in Oncology
NEWTON, MA--(Marketwire - Feb 3, 2012) - Proventys, a leading developer of personalized decision support technologies for oncology and cardiology, announced that McKesson Corporation has acquired its CDS Oncology assets.
-
Medical Device Development Group and Moffitt Cancer Center Form Tampa Medical Innovations to Commercialize Inventions
TAMPA, FL--(Marketwire - Feb 3, 2012) - Medical Device Development Group, specialists in the commercialization of medical devices, has announced a joint venture with Moffitt Cancer Center. The new organization, called Tampa Medical Innovations (TaMI), will commercialize medical device inventions envisioned by the Moffitt medical team.
-
PharmaGap In Vivo Study Results Include Indication of 80% to 88% Reduction in Ascites, 62% Reduction In Tumour Burden in Ovarian Cancer Models
OTTAWA, ONTARIO--(Marketwire - Feb. 3, 2012) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") today announced results from the most recent testing of its cancer drug Gap107B8 in mouse models of human ovarian cancer.
-
OPTIMIZERx Announces Company Updates
ROCHESTER, MI--(Marketwire - Feb 3, 2012) - OPTIMIZERx Corp (OTCBB: OPRX) announces key updates:
-
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 3, 2012) - Threshold Pharmaceuticals, Inc (NASDAQ: THLD)
-
Quidel to Hold Fourth Quarter and Full Year 2011 Financial Results Conference Call on February 29, 2012
SAN DIEGO, CA--(Marketwire - Feb 2, 2012) - Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release fourth quarter and full year 2011 financial results after market close on Wednesday, February 29, 2012.
-
Critical Outcome Technologies Inc. Identifies Phase 1 Oral Formulation Candidates for COTI-2
LONDON, ONTARIO--(Marketwire - Feb. 2, 2012) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that it has developed Phase 1 oral formulation candidates for COTI-2, a potentially first-in-class and best-in-class non-ATP competitive modulator/inhibitor of AKT/AKT2 that is being prepared for a Phase 1 clinical trial. The development of an oral formulation for use in humans attempts to maximize the amount of an orally administered drug that is absorbed and then circulates in the body.
-
Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2011 Financial Results
Company Provides Financial Guidance and Expected Milestones for 2012; Ongoing Phase II Trials of Omecamtiv Mecarbil and CK-2017357 Inform Next Steps in Clinical Development Programs
-
Companion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015
-
Molecular Insight Pharmaceuticals, Inc. Presents Human Data Demonstrating Detection of Metastatic Prostate Cancer
CAMBRIDGE, MA--(Marketwire - Feb 2, 2012) - Molecular Insight Pharmaceuticals, Inc. (MIP) will present first human data on the molecular imaging of metastatic prostate cancer in bone and soft tissue with their new 99mTc-radiolabeled compounds. The data will be highlighted at a scientific poster presentation on February 3, 2012 at the ASCO-2012 Genitourinary Cancers Symposium in San Francisco, CA. 99mTc-MIP-1404 and 99mTc-MIP-1405, internally developed at Molecular Insight, are technetium-99m-labeled small molecules that target prostate specific membrane antigen (PSMA), a protein expressed at high levels in primary and metastatic prostate cancer. The data demonstrated that 99mTc-MIP-1404 and 99mTc-MIP-1405 rapidly detected both bone and lymph node lesions in 6 metastatic prostate cancer patients and in some cases demonstrated a greater number of metastatic lesions in bone than bone scans, the standard of care for imaging skeletal metastases. Neither compound localized in the normal prostate gland, and both cleared from the blood rapidly, allowing rapid visualization of disease.
-
Pivotal Therapeutics Inc. Review and Update from the CEO
WOODBRIDGE, ONTARIO--(Marketwire - Feb. 2, 2012) - Pivotal Therapeutics Inc. (CNSX:PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health, today reports a Review and Update from the CEO.
-
American Diabetes Association Names Robert E. Ratner, MD, FACP, FACE as Organization's Chief Scientific and Medical Officer
ALEXANDRIA, VA--(Marketwire - Feb 2, 2012) - The American Diabetes Association announced today that Robert E. Ratner, MD, FACP, FACE has been named Chief Scientific and Medical Officer, effective May 7, 2012. Dr. Ratner is currently Professor of Medicine at Georgetown University Medical School and Senior Research Scientist at the MedStar Health Research Institute in metropolitan Washington, DC.
-
Announcing the 2012 International Biomass Conference & Expo Agenda
Created From More Than 240 Abstracts, the Agenda Contains the Best Presentations Gathered From Six Continents
-
MethylGene annonce la nomination de Dr Henry J. Fuchs à son conseil d'administration
MONTRÉAL, QUÉBEC--(Marketwire - 2 fév. 2012) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui la nomination de Dr Henry J. Fuchs au conseil d'administration de la Société.
-
MethylGene Announces the Appointment of Dr. Henry J. Fuchs to its Board of Directors
MONTREAL, QUEBEC--(Marketwire - Feb. 2, 2012) - MethylGene Inc. (TSX:MYG) is pleased to announce the appointment of Dr. Henry J. Fuchs to the Company's Board of Directors.
-
StayinFront Named Editors' Pick by Consumer Goods Technology Magazine for 2012
StayinFront Among Select Group Recognized for Innovation
-
New WVC Plaza, New Services, Fun Health Workouts, and Fabulous CE Are This Year's Conference Hallmarks
84th Annual Western Veterinary Conference Slated for February 19-23, 2012, in Las Vegas
-
Breaking News: Spinal Surgeon and Researcher Dr. Thaiyananthan Introduces Spinal Renewal Treatment (SRT) to World
Groundbreaking Procedure to Leave an Indelible Mark on Regenerative Medicine
-
King & Spalding Advises BioScrip in Sale of Specialty Pharmacies and Centralized Specialty and Mail Service Pharmacy to Walgreens
NEW YORK, NY--(Marketwire - Feb 2, 2012) - King & Spalding advised BioScrip, Inc. on the sale of certain assets of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens Co. for a total deal value of $225 million, which includes approximately $170 million in cash at closing and retention by BioScrip of associated accounts receivable and working capital liabilities of approximately $55 million, based on BioScrip's balance sheet values at December 31, 2011.
-
Humex Medical Signs Agreement to Establish Stem Cell Center in Vietnam
LOS ANGELES, CA--(Marketwire - Feb 2, 2012) - PHI Group, Inc. (OTCQB: PHIE) (PINKSHEETS: PHIE) announced today that Humex Medical Group, Inc. has signed an agreement with Tri Phuoc Co., Ltd, a Vietnamese company, to establish a stem cell center in Vietnam.
-
Prana Comments on Nature Medicine, PNAS and Journal of Alzheimer's Disease Articles That Highlight the Role of Metals in Neurological Diseases
MELBOURNE, AUSTRALIA--(Marketwire - Feb 2, 2012) - Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today commented on three recent high profile scientific journal articles that the company believes provide support for Prana's therapeutic strategy for treating neurodegenerative disease.
-
The Sclar Dental Implant Surgery Video Library
MIAMI, FL--(Marketwire - Feb 2, 2012) - The Sclar Center for Empowered Dental Implant Learning in Miami offers a new and unique surgical training experience for specialists and general dentists. One of the components of this unique surgical training experience is the Sclar Center's Dental Implant Surgery Video Library. This online library is extensive and constantly growing. Participants in Sclar Center courses have online access to this library for one year after attending a Sclar Center course.
-
AbCelex Technologies Announces Research Collaboration and Commercialization Agreement With the Carton Group
TORONTO, ONTARIO--(Marketwire - Feb. 2, 2012) - AbCelex Technologies Inc. is pleased to announce a strategic collaboration agreement with the Carton Group.
-
Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA
BERKELEY, CA--(Marketwire - Feb 2, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it met with the Food and Drug Administration (FDA) in a Pre-Biologics License Application (pre-BLA) meeting, and Dynavax and the FDA have agreed that the initial HEPLISAV BLA submission will be for an indication in healthy adults 18-70 years of age. This agreement represents a significant expansion of the previously anticipated population of healthy adults age 40 and over. In addition, it was confirmed that a supplemental BLA with an indication for patients with chronic kidney disease will be filed when the initial BLA is approved.
-
DeeDee Tillitt Reunites With Ken Dowell; Joins Excelsior Solutions
EDINA, MN--(Marketwire - Feb 2, 2012) - Excelsior Solutions, a leading national pharmacy consulting firm based in Minneapolis, announced today the hire of DeeDee Tillitt as the newest member of their national pharmacy consulting team.
-
OncoSec's President and CEO Explains His Firm's Ambitious List of Milestones for 2012
LOS ANGELES, CA--(Marketwire - Feb 2, 2012) - In an exclusive interview with BioMedReports, Punit Dhillon, the President and CEO of OncoSec Medical Inc. (OTCBB: ONCS), explains some of the reasons why investors may be taking positions in the company after a slow but steady sell-off in the market.
-
AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO & Investor Conference
Webcast Accessible via AVI Website
-
YouTube Interview Now Available for Kedem Pharmaceuticals CEO Dr. Hassan Salari Updating Company Progress on Sublingual Drug Delivery System
PHOENIX, AZ--(Marketwire - Feb 2, 2012) - Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to announce the company CEO Dr. Hassan Salari providing an update on the company's progress on YouTube for the Company's lead therapeutic drug for erectile dysfunction X-Excite. The Company's second lead therapeutic drug KDM-1102 is a new sublingual formulation of Propanolol. The newest drug initiated into development is Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults.
-
Frost & Sullivan Honor Underlines Courtagen Life Sciences' Commitment to Innovation, Which Facilitates Breakthroughs in Biomedical Research
Courtagen's Avantra(R) Q400 Solves Unmet Need for Walk-Away Multiplexed Protein Analysis Instrument for Clinical Settings
-
Horizon Pharma to Present at the 14th Annual BIO CEO and Investor Conference
DEERFIELD, IL--(Marketwire - Feb 2, 2012) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 1:30pm Eastern Time in New York, NY. Mr. Walbert will provide an overview of the Company and its corporate activities.
-
Del Mar Pharmaceuticals Granted U.S. Orphan Drug Designation for VAL-083 for the Treatment of Glioma
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 2, 2012) - DelMar Pharma today announced that the United States FDA Office of Orphan Products Development has granted orphan drug designation for VAL-083 for the treatment of glioma, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
VAL-083 represents a 'first in class' small-molecule chemotherapeutic, which has been assessed in multiple NCI-sponsored clinical studies. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types, including GBM. DelMar Pharma has initiated a Phase I/II clinical trial of VAL-083 in patients with recurrent GBM, from which data is anticipated later this year.
-
Warnex reporte la date d'échéance de sa débenture en cours
LAVAL, QUÉBEC--(Marketwire - 2 fév. 2012) - Warnex Inc. (TSX:WNX) (« Warnex ») est heureuse d'annoncer qu'elle a conclu une entente avec Persistence Capital Partners LP (« PCP ») en vue de reporter la date d'échéance de l'une de ses débentures convertibles en cours détenue par PCP. À l'heure actuelle, PCP détient une débenture convertible de Warnex d'un capital de 1 230 969 $ venant à échéance le 31 janvier 2012 (la « débenture de janvier 2012 ») et une autre débenture convertible de Warnex d'un capital de 346 702 $ venant à échéance le 29 février 2012. Aux termes de l'entente conclue avec PCP, Warnex a versé 250 000 $ à PCP, à titre de paiement pour tous les intérêts et frais impayés actuellement dus à PCP et à titre de remboursement partiel du capital dû aux termes de la débenture de janvier 2012, en échange d'un report au 29 février 2012 de la date d'échéance du solde de la débenture de janvier 2012.
-
Warnex Extends Maturity Date of Its Outstanding Debenture
LAVAL, QUEBEC--(Marketwire - Feb. 2, 2012) - Warnex Inc. (TSX:WNX) ("Warnex") is pleased to announce that it has reached an agreement with Persistence Capital Partners LP ("PCP") to extend the maturity date of one of its outstanding convertible debentures held by PCP. PCP currently holds a convertible debenture of Warnex in the principal amount of $1,230,969 maturing on January 31, 2012 (the "January 2012 Debenture") and a further convertible debenture of Warnex in the principal amount of $346,702 maturing on February 29, 2012. Under the terms of the agreement reached with PCP, Warnex has paid $250,000 to PCP, in payment of all outstanding interest and fees currently owing to PCP and in partial repayment of the principal amount owing pursuant to the January 2012 Debenture, in exchange for an extension of the maturity date on the balance of the January 2012 Debenture to February 29, 2012.
-
MWI Veterinary Supply Announces 2012 First Quarter Results and Updates Its 2012 Business Outlook
BOISE, ID--(Marketwire - Feb 2, 2012) - MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the "Company") announced financial results today for its first quarter ended December 31, 2011.
-
Novartis Vaccines & Diagnostics seleziona GlobalEnglish Corporation come partner principale per l'innovazione e la collaborazione aziendale
La nuova piattaforma software aziendale on-demand basata su cloud verrà impiegata per assistere i membri del team globale a comunicare e collaborare in modo più efficace ed efficiente, per ottenere un'organizzazione che opera in modo ottimale
-
Agennix AG Halts Phase II/III OASIS Trial in Severe Sepsis
PLANEGG, GERMANY and MUNICH, GERMANY--(Marketwire - Feb 2, 2012) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) (ISIN DE000A1A6XX4) announced that, upon the recommendation of the study Data Safety Monitoring Board (DSMB), the Company has stopped further enrollment and treatment in the Phase II/III OASIS trial with talactoferrin in severe sepsis. The DSMB made this recommendation based on a review of the available data from the trial, which indicated that 28-day mortality in the talactoferrin arm of the study was greater than in the placebo arm.
-
Novo Nordisk A/S: Financial Statement - Novo Nordisk increased operating profit by 18% in 2011
BAGSVAERD, DENMARK--(Marketwire - Feb 2, 2012) -
-
OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S
LEIDEN, NETHERLANDS--(Marketwire - Feb 2, 2012) - OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO), announces today that a formulation
development and
manufacturing contract has been signed with Ferring Pharmaceuticals
A/S, a
leading innovative pharmaceutical company. The undisclosed contract value
will
make a material contribution to OctoPlus' 2012 revenues. Further details
on the
compound and activities are not disclosed.
-
Octoplus Enters Into Drug Development and Manufacturing Contract With Ferring Pharmaceuticals A/S
LEIDEN, THE NETHERLANDS--(Marketwire - Feb 2, 2012) - OctoPlus N.V. ("OctoPlus" or the "Company") (AMS: OCTO), announces today that a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S, a leading innovative pharmaceutical company. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed.
-
Marina Biotech Begins Trading on the OTCQX Tier of OTC Market
BOTHELL, WA--(Marketwire - Feb 1, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's common stock will begin trading on the OTCQX tier of the OTC Markets commencing on Thursday, February 2, 2012. The Company has been advised that its shares will trade under its current symbol, "MRNA". Investors will be able to view real-time stock quotes for "MRNA" at http://www.otcmarkets.com/stock/MRNA/quote.
-
Theravance to Present at Investor Conferences in February 2012
SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 1, 2012) - Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Chief Executive Officer, is scheduled to present at the following investor conferences in February 2012:
-
Ablynx Receives Another Milestone as Boehringer Ingelheim Selects Nanobody Candidate for Pre-Clinical Development
GHENT, BELGIUM--(Marketwire - Feb 1, 2012) -
-
Tech Council of Maryland's First MdBio Leadership Networking Breakfast to Feature FDA Commissioner Margaret Hamburg
Networking Portion of Event to Focus on Employment Opportunities
-
Lightlake Therapeutics Inc. Comments on Unusual Trading Activity
LONDON--(Marketwire - Feb 1, 2012) - Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that there have been no material changes to its operations or its business affairs, and the Company is not aware of any undisclosed developments that would account for the recent unusual trading activity of its shares.
-
GI Pathology Signs Exclusive Marketing Agreement for CDx Diagnostics' Computer-Aided Brush Biopsy Test
Studies Show EndoCDx(R) EGD Enhances Detection of Barrett's Esophagus and Dysplasia by up to 40%
-
MorphoSys to Present at First German Science Day
MARTINSRIED / MUNCHEN, GERMANY--(Marketwire - Feb 1, 2012) -
-
GNC and Rock Creek Pharmaceuticals Partner to Offer Anatabloc(TM) Through GNC's Online Retail Platform
GLEN ALLEN, VA--(Marketwire - Feb 1, 2012) - Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), today announced a new partnership with GNC, the global health and wellness retailer that specializes in premium, value-added nutritional products. Beginning today, customers will be able to purchase AnatablocT through GNC's Internet storefront: http://www.gnc.com. AnatablocT assists the body's natural process for regulating inflammation using an alkaloid found in plants and vegetables, in combination with Vitamins A and D3, to help maintain healthy levels of inflammation. AnatablocT was introduced in August 2011 through a dedicated product website.
-
CardioComm Solutions Enters into the Mobile Cardiac Telemetry Arrhythmia Monitoring Software and Service Market for Cardiac Patients
TORONTO, ONTARIO--(Marketwire - Feb. 1, 2012) - CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE:EKG) and TZ Medical, Inc. (TZM, Oregon) entered into a device integration and distribution agreement for the Mobile Cardiac Telemetry (MCT) electrocardiographic (ECG) and arrhythmia management market. Under this agreement, CardioComm Solutions will integrate TZM's new Aera CTT MCT monitor into their proprietary GEMST software. The GEMST MCT offering will be called GEMS Aera CT and it will be an extension of CardioComm Solution's popular GEMST Air (Global ECG Management System) solution.
-
ALR Technologies Updates Shareholders on Its FDA-Cleared Diabetes Management System
ALR Tech Meets With U.S. Business Leaders, Policymakers: Talks Focus on How Health-e-Connect Can Improve Patient Outcomes, Lower Healthcare Costs
-
Study: E-Prescribing Shown to Improve Outcomes and Save U.S. Healthcare System Billions of Dollars
Study Quantifies Relationship Between E-Prescribing and Medication Adherence, With Potential Savings of $140 Billion Over the Next 10 Years
-
AspenBio Sets 2012 AppyScore Anticipated Milestones; Sees Pivotal Clinical Trial for Appendicitis Test Beginning Mid-2012
Following Major Portion of R&D Effort Completion and Expense Reductions, Cash Runway Extends to Advance 2012 Objectives
-
Miraculins' PreVu Test Cleared for Sale by Health Canada
WINNIPEG, MANITOBA--(Marketwire - Feb. 1, 2012) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that its PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test has been cleared for sale by Health Canada.
-
Ardea Biosciences Prices Public Offering of Common Stock
SAN DIEGO, CA--(Marketwire - Feb 1, 2012) - Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering are expected to be $144.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ardea. Ardea has granted the underwriters a 30-day option to purchase up to an aggregate of 1,275,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about February 6, 2012, subject to customary closing conditions. Ardea anticipates using the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to Phase 3 clinical trials of lesinurad, capital expenditures, working capital, and general and administrative expenses.
-
Biotech Dealmaking Gets Off to a Strong Start in 2012
Roche's Hostile $5.7 Billion Bid for Illumina Sets the Stage for a Protracted Fight, Burrill & Company Says
-
Daxor Announces That Shertech Pharmacy Corp. Acquires BVA-100 Blood Volume Analyzer to Service Multiple Hospitals
NEW YORK, NY--(Marketwire - Feb 1, 2012) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Shertech Pharmacy in Greenville, South Carolina. This agreement will provide Shertech with a Daxor BVA-100 Blood Volume Analyzer, an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis. Published studies using the BVA-100 have shown that blood volume measurement is important in treating heart failure, critical care patients in intensive care units, and in diagnosing the true status of complex anemias and syncope (fainting).
-
Syngenta Releases Innovotech from Right of First Refusal Obligation
EDMONTON, ALBERTA--(Marketwire - Feb. 1, 2012) - Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product development, today announced that Syngenta AG has decided not to pursue its Right of First Refusal for Innovotech's seed treatment product, Agress®.
-
Novartis Vaccines & Diagnostics Selects GlobalEnglish Corporation as Its Premier Partner in Enterprise Innovation and Collaboration
New On-Demand Cloud-Based, Enterprise Software Platform Employed to Help Global Team Members Communicate and Collaborate More Effectively and Efficiently, Leading to an Optimally Operating Organization
-
Novo Nordisk A/S - Share repurchase programme
BAGSVAERD, DENMARK--(Marketwire - Feb 1, 2012) -
-
Precision Dynamics Corporation - St. John Awarded Amerinet Contracts for Identification Solutions and Other Healthcare Products
Agreement Provides Guaranteed Savings Through ValuePlus(TM) Product Standardization Service
-
LawyersandSettlements.com Recognizes American Heart Month With Its Top 10 Heart Lawsuit Topics for 2011
Diabetes Drug, Antidepressants Top the List of Those Alleging Heart Side Effects
-
Market Research Projects HIV/AIDS Testing Market Growth at 5.2% CAGR Through 2014
-
MagForce AG Announces Capital Increase from Authorized Capital
BERLIN, GERMANY--(Marketwire - Feb 1, 2012) -
-
REGiMMUNE Initiates Phase I/II Clinical Trial for GvHD
Company Raises 5 Million Dollars in Series A Preferred to Fund Trial
-
When Romney Advisor Speaks on "BioCentury This Week" TV the National News Media Listens
Romney Advisor Norm Coleman Made Waves on "BioCentury This Week" Television When He Predicted a GOP President Will Not Repeal the Affordable Care Act; The News was Instantly Picked Up by More Than 20 National News and Political Sites; The Romney Campaign Quickly Responded That it Remains Committed To Repealing "Obamacare"
-
Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy
MDV3100 Prolonged Life by 4.8 Months Compared to Placebo and Met All Secondary Endpoints
Medivation to Host Conference Call at 4:30PM Eastern Time on Thursday, February 2
-
Helix BioPharma Corp. informiert Aktionäre über Ergebnisse der Jahreshauptversammlung
AURORA, ON--(Marketwire - Jan 31, 2012) -
Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (das "Unternehmen" oder "Helix") gibt bekannt, dass die Jahreshauptversammlung ("JHV" oder die "Versammlung") heute wie geplant stattgefunden hat. Auf der JHV wurde der Jahresabschluss des Unternehmens vorgestellt und das Mandat der Abschlussprüfer KPMG LLP Chartered Accountants wurde erneuert.
-
Helix BioPharma Corp. informiert Aktionäre über Ergebnisse der Jahreshauptversammlung
AURORA, ON--(Marketwire - Jan 31, 2012) -
Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (das "Unternehmen" oder "Helix") gibt bekannt, dass die Jahreshauptversammlung ("JHV" oder die "Versammlung") heute wie geplant stattgefunden hat. Auf der JHV wurde der Jahresabschluss des Unternehmens vorgestellt und das Mandat der Abschlussprüfer KPMG LLP Chartered Accountants wurde erneuert.
-
Premier has Been Granted a Management Cease Trade Order
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 31, 2012) -
-
Tibet Pharmaceuticals Signs Letter of Intent to Cooperate With Anhui Taihe Pharmaceutical Group
Strategic Cooperation Anticipated to Extend Tibet Pharmaceuticals' Distribution Network in China
-
Ardea Biosciences Announces Proposed Public Offering of Common Stock
SAN DIEGO, CA--(Marketwire - Jan 31, 2012) - Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
-
InDevR Expands Commercialization Team to Meet Market Demand
BOULDER, CO--(Marketwire - Jan 31, 2012) - InDevR, Inc., a Boulder-based biotechnology company developing advanced life science instrumentation and assays for analysis of viruses and other microorganisms, announced today the appointment of Dr. Michael Artinger as Vice President of Commercial Operations and Mr. Craig Hoechstetter as Director of Sales and Customer Support.
-
Recombinant Data Executive Re-Elected to Clinical Data Interchange Standards Consortium (CDISC) Board of Directors
Dr. David Hardison to Help Shape Healthcare Data Standards to Advance Personalized Medicine
-
Stratos Product Development Lends Critical Design Expertise to Mimic Technologies' dV-Trainer Surgical Training Device
SEATTLE, WA--(Marketwire - Jan 31, 2012) - Stratos Product Development LLC today announced its partnership with Mimic Technologies to advance the current design of the Mimic dV-Trainer, an independently validated, highly realistic simulation system for the da Vinci robot that improves patient safety and allows for surgical training, saving operating room time and reducing operational costs.
-
PCI Synthesis Adds Manufacturing, QC, Business, and R&D Expertise
NEWBURYPORT, MA and NEW ORLEANS, LA--(Marketwire - Jan 31, 2012) - Informex, Booth 425 -- PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has significantly increased its bench strength in quality control and research and development with the hiring of several experts in recent months.
-
POR Launches PharmaCONNECT Desktop Drug Reference Database
A Free, Online Go-To Resource for Physicians to Get Authoritative Information on All FDA-Regulated Drugs
-
Functional Technologies Announces Management Changes to Facilitate Strategic Relationship Development Efforts
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 31, 2012) - Functional Technologies Corp. (TSX VENTURE:FEB) (the "Company") announced Mr. Christopher Morris has been appointed Acting Chief Executive Officer (CEO). This enables Mr. Howard Louie, who remains as Executive Chairman and assumes the responsibilities of Chief Business Development Officer (CBDO), to focus exclusively on the Company's activities in cultivating and executing on strategic relationships associated with its lead technologies, as well as his ongoing capital market efforts.
-
West to Present at UBS Conference
LIONVILLE, PA--(Marketwire - Jan 31, 2012) - West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will attend the UBS 22nd Annual Global Healthcare Services Conference in New York, NY. Management will present an overview of West's business and outlook on Tuesday, February 7, 2012 at 3:00 PM ET.
-
Market Research Projects Diabetes Devices Market at $20 Billion by 2014
-
Reflect Scientific, Inc. Has Positive Outlook for 2012
OREM, UT--(Marketwire - Jan 31, 2012) - Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries announced a letter to shareholders outlining the 2012 strategic plan.
-
Cytovance(R) Biologics Manufacturing Capacity Grows
OKLAHOMA CITY, OK--(Marketwire - Jan 31, 2012) - Cytovance Biologics® announced today that it is has added a 1,000L bioreactor to its current mammalian facility with appropriate downstream processing facilities. Cytovance Biologics® currently specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from batch, fed-batch and perfusion processes and microbial production up to the 100L scale.
-
Am Law 200 Polsinelli Shughart Chooses IPRO Eclipse as Firm-Wide Review Platform
Comprehensive Review Software Allows Firm to Migrate From Legacy Systems to a Single All-in-One Electronic Discovery Platform
-
Genetic Technologies Files Quarterly Activities Report and ASX Appendix 4C for Quarter Ended December 31, 2011
MELBOURNE, AUSTRALIA--(Marketwire - Jan 31, 2012) - Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced it has filed its Quarterly Activities Report and Appendix 4C for period ending December 31, 2011 in accordance with the ASX.
-
Market Research Projects Dental Implants Market at $4 Billion by 2014
-
Sobi: Wills Hughes-Wilson appointed Vice President Government Affairs & Policy
STOCKHOLM, SWEDEN--(Marketwire - Jan 31, 2012) -
-
First Naviscan PET Scanner Installed in Turkey
Positron Emission Mammography Now Available at MEDICA Medical Center
-
Helix BioPharma Corp. Updates Shareholders on Results From Annual General Meeting
AURORA, ON--(Marketwire - Jan 30, 2012) - Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (the "Company" or "Helix") announces that its Annual General Meeting ("AGM" or the "Meeting"), was held today as scheduled. The financial statements of the Company were placed before the AGM and the auditors, KPMG LLP Chartered Accountants, were reappointed.
-
Pacgen Expands PAC-113 License
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE:PGA) announced today that the Company has signed an amendment to its license agreement with Demegen, Inc., to expand its exclusive worldwide rights and license to PAC-113 for additional indications, including vaginal, dermatological and ophthalmic applications. There was no payment associated with the amendment license agreement. All other terms of the license agreement remained unchanged. Pacgen has right to sublicense all these additional indications as well as oral indications covered in its original license.
-
Medistem and ERCell Initiate Phase II RECOVER-ERC Heart Failure Trial
First Three Patients Successfully Treated With ERC Stem Cell Using Novel "Retrograde Procedure"
-
MichBio Launches Medical Devices Committee to Enhance Sector Support and Growth Statewide
ANN ARBOR, MI--(Marketwire - Jan 30, 2012) - MichBio announced that it has formed a Medical Devices, Technology & Manufacturing Committee to enhance its representation and resource capacity for this important biosciences industry sector.
-
Show Us Your Moves
American Diabetes Association's Diabetes Forecast Profiles the Many Forms, Benefits of Exercise
-
Tech Council of Maryland Appoints Art Jacoby as Interim CEO
ROCKVILLE, MD--(Marketwire - Jan 30, 2012) - The Tech Council of Maryland (TCM), Maryland's largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today announced that Art Jacoby, a TCM board member and managing partner at Maryland Cyber Investment Partners, will serve as the association's interim CEO.
-
InterMed Installs Maine's First Low-Dose Computed Tomography (CT) System
General Electric's New CT Technology Reduces Radiation Dosage by up to 40 Percent; InterMed Houses the Second State-of-the-Art Unit in North America
-
BroadcastMed Launches Online Video Channel for NewYork-Presbyterian
FARMINGTON, CT--(Marketwire - Jan 30, 2012) - BroadcastMed, Inc. is proud to present the health community with an online resource for quality, video content. The recently launched NEP Video Center contains videos on specialties ranging from cancer to pediatrics to orthopedics. This Wednesday, a new program launches on the site highlighting the otolaryngology department at NewYork-Presbyterian. Viewers will learn from top specialists on treating a wide-range of ear, nose, and throat conditions.
-
T-System Launches Solution to Strengthen Physician Alignment, Support ACO Model
T-System Boosts Revenue by Enabling Better Care Coordination of the Patient-Handoff Process Through Automated Workflow and Communication Tools
-
ORLive Program Tackles Thyroid Surgery
FARMINGTON, CT--(Marketwire - Jan 30, 2012) - There are a variety of reasons why thyroid surgery is performed including thyroid cancer, problems related to enlarged thyroid, and treatment for hyperthyroidism. This Wednesday, online views will get a firsthand look at how surgeons perform a thyroidectomy during a live webcast program from Homestead Hospital in Homestead, Florida. General surgeon, George Tershakovec, MD, will perform the procedure and viewers are encouraged to email questions to the operating room.
-
Rock Creek Pharmaceuticals Reports First Clinical Trial Showing Anatabloc(TM) Lowers Chronic Inflammation Measured by CRP Blood Levels in Humans
GLEN ALLEN, VA--(Marketwire - Jan 30, 2012) - Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), has completed the first successful human clinical trial showing that AnatablocT, the dietary supplement developed by Rock Creek to provide anti-inflammatory support, lowers C-reactive protein (CRP) levels in subjects' blood. CRP is a molecule produced by the liver in response to an inflammatory signal, and is a marker for inflammation. The company is today reporting initial results from Phase 2 of the RCP-006 study titled "A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Efficacy of AnatablocT, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers, Followed by an Open-Label Extension Period." The trial consisted of 105 subjects, all of whom were smokers and 79% of whom were overweight or obese. Research increasingly links inflammation to a variety of diseases such as Alzheimer's disease, thyroiditis and diabetes, as well as cardiovascular disease.
-
SOHM Expands Its Dermatology Division by Introducing Five Additional Products
BUENA PARK, CA--(Marketwire - Jan 30, 2012) - SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceuticals, nutraceutical and dermatology company that manufactures and markets generic drugs covering all major treatment categories, today announced its launch of additional dermatology products into Indian market.
-
Miraculins PreVu Test CE Marked and Registered in the European Union
Company Readies for European Sales and Marketing
-
CincyTech Invests in Recent Brandery Graduate
Choremonster Bridges the Digital Gap Between Parents and Children
-
RepliCel Provides Quarterly Update on First-In-Man Clinical Trials
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB:REPCF) is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.
-
biOasis Advances its Herceptin(R) BT2111 Program
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman - both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors.
-
Genome British Columbia: Beating Childhood Brain Cancer-A Success Story
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - In March of 1993, Penny Flynn and Jeff Date received devastating news: their nine-month-old daughter Taylor had been diagnosed with medulloblastoma, a cancerous brain tumour. Cancer is the leading cause of non-accidental deaths in children, and medulloblastoma is the most common form of childhood cancer. The few children who do survive the aggressive and debilitating treatments must then often cope with a host of side-effects, such as learning challenges and physical disabilities. In essence, saving the child's life is an important initial victory, but also the start of life-long challenges for the child, their family and the health care system.
-
SpectraScience Names Hughes Wielemans as Director of Business Development in Europe
SAN DIEGO, CA--(Marketwire - Jan 30, 2012) - SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE), a San Diego based medical device company, today announced it has named Hughes Wielemans as Director of Business Development, Europe, effective February 1.
-
ISTA's Board Reiterates Commitment to Maximizing Shareholder Value Through Strategic Review Process
IRVINE, CA--(Marketwire - Jan 30, 2012) - The Board of Directors of ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today reiterated its commitment to maximizing shareholder value and said it will continue its previously announced review of all strategic options available to the Company. The Board issued its statement in response to a press release from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announcing that Valeant had withdrawn its unsolicited proposal to acquire ISTA.
-
Plandai Biotechnology, Inc. Announces Appointment of World-Renowned Physicist to Chair Plandai Scientific Board
SEATTLE, WA--(Marketwire - Jan 30, 2012) - Plandaí Biotechnology, Inc. (OTCBB: PLPL) Chief Executive Officer, Roger Duffield, today announced that Dr. Tom Matula has accepted the position of Chairman of the Scientific Board for Plandaí Biotechnology, Inc., effective immediately.
-
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
SAVI-PCI (pronounced savvy) will be a randomized, open-label study enrolling approximately 600 patients undergoing percutaneous coronary intervention (PCI) at sites across the United States. The study is designed to evaluate whether patients receiving the investigational, High-Dose Bolus (HDB) regimen of AGGRASTAT (25 mcg/kg bolus over 3 minutes) followed by an infusion of 0.15 mcg/kg/min for a shortened duration of 2 hours will have outcomes that are similar, or "non-inferior," to patients receiving an 18 hour infusion of Integrilin® (eptifibatide) (Merck & Co., Inc.) at its FDA approved dosing regimen. The primary objective of SAVI-PCI is to demonstrate AGGRASTAT is non-inferior to Integrilin with respect to the composite endpoint of death, PCI-related myocardial infarction, urgent target vessel revascularization, or major bleeding within 48 hours following PCI or hospital discharge. The secondary objectives of this study include the assessment of safety as measured by the incidence of major bleeding. The first patient is anticipated to be enrolled in spring 2012. The Principal Investigator for the study is Steven V. Manoukian, MD, Director of Cardiovascular Research at the Sarah Cannon Research Institute (SCRI).
-
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
SAN DIEGO, CA--(Marketwire - Jan 30, 2012) - Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) to treat a form of coronary heart disease, chronic myocardial ischemia (CMI). The IDE application was originally submitted to the FDA in December 2011.
-
Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials
Canadian Centre of Excellence Partners With US-Based Molecular Insight Pharmaceuticals to Manufacture a New Radiopharmaceutical for Clinical Trials That Will Evaluate the Potential to Deliver Targeted Radiotherapy Directly to Metastatic Prostate Cancer
-
ISTA Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis
IRVINE, CA--(Marketwire - Jan 30, 2012) - ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced it has successfully enrolled more than 600 patients in the Company's Phase 2 clinical study of its BEPOSONET nasal spray combining bepotastine besilate with a steroid for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study is evaluating the safety and efficacy of the combination nasal spray, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.
-
BioExx Provides Business Update
|